Onkure Therapeutics, Inc. (OKUR) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Onkure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines targeting PI3Kα mutations for vascular anomalies and cancers. The company operates as a single segment (clinical research) and has no approved products or product revenue. Following a reverse recapitalization merger in October 2024, the company completed a significant capital raise in March 2026.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | Balance Sheet (June 30, 2026) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(15.3) million | $(30.5) million | N/A |
| Operating Expenses | $16.9 million | $32.5 million | N/A |
| Cash & Equivalents | N/A | N/A | $166.5 million |
| Marketable Securities | N/A | N/A | $9.9 million |
| Total Liquidity | N/A | N/A | $176.4 million |
| Accumulated Deficit | N/A | N/A | $(244.7) million |
| Net Cash Used in Operations (YTD) | N/A | $(23.3) million | N/A |
Material Changes vs. Prior Period
- Capital Raise: In March 2026, the company closed a Private Placement (PIPE) raising approximately $150.0 million in gross proceeds. This significantly increased cash reserves from $59.1 million at year-end 2025 to $166.5 million at June 30, 2026.
- Operating Expenses: For the six months ended June 30, 2026, total operating expenses decreased by $0.8 million compared to the same period in 2025. This was driven by a $1.3 million decrease in R&D expenses (due to reduced outsourced preclinical costs), partially offset by a $0.5 million increase in G&A expenses.
- Interest Income: Interest income increased to $1.6 million for Q2 2026 from $0.9 million in Q2 2025, reflecting higher cash balances available for investment following the capital raise.
- Share Count: Weighted average shares outstanding increased significantly to ~49.9 million for Q2 2026 from ~13.5 million in Q2 2025 due to the issuance of shares and pre-funded warrants in the 2026 Private Placement.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash, cash equivalents, and marketable securities ($176.4 million) are sufficient to fund operations for at least the next 12 months. The substantial doubt regarding the company's ability to continue as a going concern, noted as of December 31, 2025, has been alleviated by the March 2026 financing.
- Development Pipeline: The company plans to submit Investigational New Drug (IND) applications for its lead candidates, OKI-345 (breast cancer) and OKI-355 (vascular anomalies), in the first half of 2027.
- Strategic Shift: The company has discontinued independent clinical development of its former lead candidate, OKI-219, to focus resources on OKI-345 and OKI-355.
- Legal Proceedings: Two shareholder complaints regarding the 2024 Merger remain pending in New York Supreme Court. While plaintiffs have not actively pursued claims, the company intends to defend vigorously.
- Risk Factors: Key risks include the failure of clinical trials to demonstrate safety/efficacy, inability to secure additional capital in the future, reliance on third-party manufacturers (single-source suppliers), and potential regulatory delays or changes in FDA policy.
Investor Verification Checklist
- Verify the specific terms and lock-up periods associated with the 2026 Private Placement and the 9.4 million pre-funded warrants issued.
- Confirm the timeline and regulatory feedback for the planned IND submissions for OKI-345 and OKI-355 in H1 2027.
- Monitor the status of the pending merger-related litigation (Thomas v. Reneo and Kent v. Reneo) for any new developments.
- Assess the company's reliance on single-source suppliers for drug substance and product manufacturing and the risks associated with supply chain disruptions.
- Review the burn rate relative to the $176.4 million liquidity position to validate the 12-month runway estimate.